Log in
Log in
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     
Sign up
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     
  1. Homepage
  2. Equities
  3. Japan
  4. Japan Exchange
  5. GNI Group Ltd.
  6. News
  7. Summary
    2160   JP3386370005

GNI GROUP LTD.

(2160)
  Report
Delayed Japan Exchange  -  02:00 2022-10-07 am EDT
1235.00 JPY   -2.60%
03:22aGni : forms joint venture with EPS in Japan focusing on medical device business
PU
10/03Gni : Monthly Update on the 47th Series Stock Acquisition Rights (Moving Strike Warrants) Exercise Status
PU
09/01Gni : Monthly Update on the 47th Series Stock Acquisition Rights (Moving Strike Warrants) Exercise Status
PU
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisionsFunds 
SummaryMost relevantAll NewsOther languagesPress ReleasesOfficial PublicationsSector news

GNI : Business Plan and Growth Potential

03/31/2022 | 03:06am EDT

© 2022 GNI Group Ltd. All rights reserved

Securities Code: 21610

Disclaimer

Forward-looking Statements

  • Statements contained herein with respect to our current plans, estimates and strategies that are not historical facts are forward-looking statements.

  • Forward-looking statements are based on our management's beliefs in light of information currently available. Actual results may differ materially from these forward-looking statements due to a variety of risks and uncertainties. Therefore, please do not rely on these forward-looking statements to make investment decisions.

  • Important factors that could affect actual results include economic and /or regulatory conditions involving the Group's business segments, market trends, and global conditions.

  • Note: In places, pro forma figures may be rounded to underscore direction of the business.

Key Updates

Executive Summary

  • Research & Development

Beijing Continent (BC)

F351 Phase III clinical trial started in Jan 2022 for HBV-induced liver fibrosis targeting NMPA application in Q2 2024 in China.

F573 Phase I clinical trial also started in Jan 2022 for acute / acute-on-chronic liver failures also in China.

Cullgen Inc.

Lead PROTAC drug molecule pre-IND consultation with China's NMPA.

  • Corporate Finance

    • - Consolidated revenue reached JPY12,690 million in FY2021, the highest in history

    • - BC filed an application for listing of the H-shares on the Main Board of The Stock Exchange of Hong Kong (HKEx).

  • 1. Corporate Profile

  • 2. Business

  • 3. Growth Strategy

  • 4. Companies

  • 5. Market Environment

  • 6. Business Outlook

  • 7. Risk Considerations

Corporate Profile

Head office address

Corporate Profile

Nihonbashi-Honcho YS Bldg. 3F 2-2-2 Nihonbashi-Honcho, Chuo-ku,

Tokyo 103-0023, Japan

Business

A global healthcare company that focuses on pharmaceutical drug development and distribution, and biomaterials

Establishment

November 2001

President and CEO

Ying Luo, Ph.D.

Paid-up Capital 10,884 million JPY

(as of the end of December 2021)

Employees (aggregate)

629 full-time employees

(as of the end of December 2021)

Listing

Tokyo Stock Exchange Mothers Market

(August 2007 / Code : 2160)

Auditor

Grant Thornton Taiyo LLC

This is an excerpt of the original content. To continue reading it, access the original document here.

Disclaimer

GNI Group Limited published this content on 31 March 2022 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 31 March 2022 07:05:09 UTC.


© Publicnow 2022
All news about GNI GROUP LTD.
03:22aGni : forms joint venture with EPS in Japan focusing on medical device business
PU
10/03Gni : Monthly Update on the 47th Series Stock Acquisition Rights (Moving Strike Warrants) ..
PU
09/01Gni : Monthly Update on the 47th Series Stock Acquisition Rights (Moving Strike Warrants) ..
PU
08/25Gni : FY2022 Q2 Analyst Call Q&A Summary
PU
08/16Gni : Q2 FY2022 Financial Results Corporate Presentation
PU
08/15Gni : Consolidated Financial Results for Q2 FY2022, Cumulative YTD (IFRS)
PU
08/15Gni : Consolidated Financial Results for Q2 FY2022(IFRS)
PU
08/15GNI Group Ltd. Provides Consolidated Earnings Guidance for the Fiscal Year Ending Decem..
CI
08/09Gni : NMPA has approved GNI Group's Subsidiary Cullgen's IND for TRK Degrader Clinical Tri..
PU
08/01Gni : Monthly Update on the 47th Series Stock Acquisition Rights (Moving Strike Warrants) ..
PU
More news
Financials
Sales 2022 16 406 M 113 M 113 M
Net income 2022 1 099 M 7,57 M 7,57 M
Net Debt 2022 - - -
P/E ratio 2022 53,4x
Yield 2022 -
Capitalization 58 646 M 404 M 404 M
Capi. / Sales 2022 3,57x
Capi. / Sales 2023 3,00x
Nbr of Employees 629
Free-Float 93,3%
Chart GNI GROUP LTD.
Duration : Period :
GNI Group Ltd. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends GNI GROUP LTD.
Short TermMid-TermLong Term
TrendsBearishNeutralNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 1
Last Close Price 1 235,00 JPY
Average target price 2 100,00 JPY
Spread / Average Target 70,0%
EPS Revisions
Managers and Directors
Ying Luo Executive President, CEO & Representative Director
Joseph F. Meyer Chief Financial Officer & Director
Hideaki Sashiwa Independent Outside Director
Thomas Wilson Eastling Director
Kanichiro Suzuki Outside Director
Sector and Competitors
1st jan.Capi. (M$)
GNI GROUP LTD.-14.38%416
MODERNA, INC.-50.72%48 959
LONZA GROUP AG-33.30%38 145
IQVIA HOLDINGS INC.-33.53%34 978
SEAGEN INC.-11.85%25 135
ALNYLAM PHARMACEUTICALS, INC.18.54%24 290